MedTrace Logo

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

NCT06176729 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-12-20

No results posted yet for this study

Summary

This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).

Conditions

Interventions

DRUG

Polatuzumab Vedotin, Rituximab, Lenalidomide

polatuzumab vedotin 1.8 mg/kg ivgtt D1, rituximab375 mg/m2 ivgtt D1, lenalidomide 25mg po D1-14, one cycle every 21 days

Sponsors & Collaborators

  • Peking University Third Hospital

    collaborator OTHER

  • Peking University First Hospital

    collaborator OTHER

  • Chinese PLA General Hospital

    collaborator OTHER

  • Yan Zhang, MD

    lead OTHER

Principal Investigators

  • Yan Zhang, MD · Peking Union Medical College Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-24
Primary Completion
2025-10-24
Completion
2027-10-24

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06176729 on ClinicalTrials.gov